34 institutions hold shares in Aerpio Pharmaceuticals Inc. (ARPO), with 7.62M shares held by insiders accounting for 16.18% while institutional investors hold 49.55% of the company’s shares. The shares outstanding are 42.14M, and float is at 32.86M with Short Float at 3.78%. Institutions hold 41.53% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Orbimed Advisors LLC. with over 5.19 million shares valued at $7.79 million. The investor’s holdings represent 12.80% of the ARPO Shares outstanding. As of Sep 29, 2020, the second largest holder is Ikarian Capital, LLC with 3.94 million shares valued at $5.91 million to account for 9.72% of the shares outstanding. The other top investors are Citadel Advisors LLC which holds 2.05 million shares representing 5.05% and valued at over $3.08 million, while Renaissance Technologies, LLC holds 4.43% of the shares totaling 1.8 million with a market value of $1.76 million.
Aerpio Pharmaceuticals Inc. (NASDAQ: ARPO) is 97.96% higher on its value in year-to-date trading and has touched a low of $0.42 and a high of $2.31 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ARPO stock was last observed hovering at around $1.97 in the last trading session, with the day’s loss setting it -0.03% off its average median price target of $1.75 for the next 12 months. It is also 3.0% off the consensus price target high of $2.00 offered by 2 analysts, but current levels are -29.33% lower than the price target low of $1.50 for the same period.
Currently trading at $1.94, the stock is 17.68% and 37.74% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.12 million and changing -1.52% at the moment leaves the stock 44.07% off its SMA200. ARPO registered 179.14% gain for a year compared to 6-month loss of 22.01%. The firm has a 50-day simple moving average (SMA 50) of $1.4648 and a 200-day simple moving average (SMA200) of $1.4395.
The stock witnessed a 48.09% gain in the last 1 month and extending the period to 3 months gives it a 9.60%, and is -4.43% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.09% over the week and 9.19% over the month.
Aerpio Pharmaceuticals Inc. (ARPO) has around 12 employees, a market worth around $90.02M and $15.00M in sales. Profit margin for the company is -27.00%. Distance from 52-week low is 361.90% and -16.02% from its 52-week high.
Aerpio Pharmaceuticals Inc. (ARPO) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Aerpio Pharmaceuticals Inc. (ARPO) is a “Overweight”. 2 analysts offering their recommendations for the stock have an average rating of 2.00, where 1 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Aerpio Pharmaceuticals Inc. is expected to release its quarterly report on 05/13/2021 and quarterly earnings per share for the current quarter are estimated at -$0.13.The EPS is expected to shrink by -87.10% this year.
Aerpio Pharmaceuticals Inc. (ARPO) Insider Activity
A total of 2 insider transactions have happened at Aerpio Pharmaceuticals Inc. (ARPO) in the last six months, with sales accounting for 1 and purchases happening 1 times. The most recent transaction is an insider sale by ORBIMED ADVISORS LLC, the company’s 10% Owner. SEC filings show that ORBIMED ADVISORS LLC sold 21,400 shares of the company’s common stock on Dec 08 at a price of $1.96 per share for a total of $41944.0. Following the sale, the insider now owns 0.0 shares.
Aerpio Pharmaceuticals Inc. (ARPO): Who are the competitors?
Omeros Corporation (OMER) is 61.81% up on the 1-year trading charts. Short interest in the company’s stock has fallen -11.29% from the last report on Dec 30, 2020 to stand at a total of 1.38 million short shares sold with a short interest ratio of 0.47.